Open Access

Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease

  • Authors:
    • Athanasios Hoursalas
    • Konstantinos Tsarouhas
    • Christina Tsitsimpikou
    • Genovefa Kolovou
    • Alexander Vardavas
    • Ioannis Hoursalas
    • Demetrios A. Spandidos
    • Haralampos Milionis
    • Moses Elisaf
    • Stavroula Tsiara
  • View Affiliations

  • Published online on: May 13, 2022     https://doi.org/10.3892/etm.2022.11371
  • Article Number: 444
  • Copyright: © Hoursalas et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A significant number of cardiovascular disease (CVD) patients, with the target lipid levels, as set by the guidelines, achieved, continue to remain at risk. In this setting, lipoprotein (Lp) a role in CVD prognosis is regaining interest. Although Lp(a) is related to the arteriosclerotic process, there is not currently an adequate amount of data for the inclusion of Lp(a) levels as a primary therapeutic target in the treatment of coronary artery disease (CAD) patients. In this framework, the current retrospective study aims to investigate the association of Lp(a) levels with the adverse cardiovascular (CV) events presented in a 10 year follow‑up of CVD patients with dyslipidemia and its association with the major CV risk factors. A statistically significant reduction in Lp(a) levels was observed during the follow‑up period (72.8±45.6 vs. 68.3±41.8 mg/dl; McNemar test; P<0.001). The vast majority of patients who suffered a new acute myocardial infarction during the follow up period had Lp(a) levels >30 mg/dl (24/28 patients, mean ± standard deviation Lp(a), 83.1±36.6 mg/dl, P=0.001). Kaplan‑Meier survival analysis did not find statistically significant differences in a percutaneous coronary intervention (PCI) time occurrence during the follow‑up period between patients with low (≤30 mg/dl) and high (>30 mg/dl) Lp(a) levels (log‑rank P=0.305). On the other hand, when a second and third PCI conducted during the monitoring period were included in the Kaplan Meier analysis as events, the mean time for a PCI was significantly shorter (7.2%; P=0.01) for patients with Lp(a) levels >30 mg/dl. In conclusion, the current study reported that patients with high Lp(a) values are more prone to the occurrence of new myocardial infarction, while the Lp(a) cut‑off value of 30 mg/dl was linked in CVD patients to an earlier need for PCI, especially in the most vulnerable group of patients with more than one (recurrent) revascularizations.
View Figures
View References

Related Articles

Journal Cover

July-2022
Volume 24 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hoursalas A, Tsarouhas K, Tsitsimpikou C, Kolovou G, Vardavas A, Hoursalas I, Spandidos DA, Milionis H, Elisaf M, Tsiara S, Tsiara S, et al: Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease. Exp Ther Med 24: 444, 2022
APA
Hoursalas, A., Tsarouhas, K., Tsitsimpikou, C., Kolovou, G., Vardavas, A., Hoursalas, I. ... Tsiara, S. (2022). Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease. Experimental and Therapeutic Medicine, 24, 444. https://doi.org/10.3892/etm.2022.11371
MLA
Hoursalas, A., Tsarouhas, K., Tsitsimpikou, C., Kolovou, G., Vardavas, A., Hoursalas, I., Spandidos, D. A., Milionis, H., Elisaf, M., Tsiara, S."Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease". Experimental and Therapeutic Medicine 24.1 (2022): 444.
Chicago
Hoursalas, A., Tsarouhas, K., Tsitsimpikou, C., Kolovou, G., Vardavas, A., Hoursalas, I., Spandidos, D. A., Milionis, H., Elisaf, M., Tsiara, S."Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease". Experimental and Therapeutic Medicine 24, no. 1 (2022): 444. https://doi.org/10.3892/etm.2022.11371